{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:24:19Z","timestamp":1794032659484,"version":"4.8.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a highly heterogeneous disorder with distinct phenotypes that can develop well before motor symptoms appear. Recently, two main phenotypes based on the different pathological spreading patterns of PD have been proposed: \u201cbody-first\u201d, where \u03b1-synuclein pathology begins in the peripheral nervous system and spreads symmetrically from bottom-up, and \u201cbrain-first\u201d, where pathology starts in the brain and spreads asymmetrically downwards. However, no studies have assessed these phenotypes across both prodromal and clinical PD stages, tracked their pathological progression in vivo or identified potential underlying biological mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address this, we analyzed 910 prodromal and 1120 clinical PD cases with comprehensive longitudinal clinical, imaging, and genetic data from the Parkinson Progression Marker Initiative over a 12-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings revealed that both prodromal and clinical groups with body-first symptoms exhibited greater motor dysfunction, anxiety, and depression at baseline; as well as worse longitudinal motor progression and attention decline compared to brain-first cases. The body-first and brain-first phenotypes were stable over time and predicted conversion to clinical PD in prodromal cases, and were also found using unsupervised deep learning analyses. Additionally, body-first cases displayed more pronounced changes in the caudal LC, as well as symmetrical alterations in the striatum and glymphatic system, consistent with the traditional bottom-up progression described by Braak\u2019s staging of \u03b1-synuclein pathology and the more symmetric distribution proposed for body-first PD. In contrast, brain-first cases exhibited changes in the rostral LC and asymmetric alterations in the striatum and glymphatic system, suggesting a top-down progression. Genetic analysis also identified new specific single nucleotide polymorphisms associated with PD phenotypes, such as\n                      <jats:italic>TRIM40<\/jats:italic>\n                      and\n                      <jats:italic>IP6K2<\/jats:italic>\n                      , linked to worse motor and cognitive outcomes in prodromal cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings emphasize the importance of recognizing body-first and brain-first PD as distinct entities with unique clinical, imaging, and genetic profiles, paving the way for targeted and personalized therapeutic strategies that address the specific pathophysiological mechanisms of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00866-5","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:09:30Z","timestamp":1750432170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical progression and genetic pathways in body-first and brain-first Parkinson\u2019s disease"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8695","authenticated-orcid":false,"given":"Massimiliano","family":"Passaretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ver\u00e9b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mite","family":"Mijalkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Zufiria-Gerbol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"2","key":"866_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2.","journal-title":"Lancet Neurol"},{"issue":"4","key":"866_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM, et al. Accurate detection of \u03b1-Synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with parkinson\u2019s disease in the DeNovo Parkinson (DeNoPa) cohort. Mov Disord. 2023;38(4):567\u201378. https:\/\/doi.org\/10.1002\/mds.29329.","journal-title":"Mov Disord"},{"issue":"7 Suppl 1","key":"866_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1212\/WNL.0000000000200793","volume":"99","author":"D Berg","year":"2022","unstructured":"Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson disease prevention: conclusion and outlook. Neurology. 2022;99(7 Suppl 1):76\u201383. https:\/\/doi.org\/10.1212\/WNL.0000000000200793.","journal-title":"Neurology"},{"issue":"5","key":"866_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of parkinson\u2019s disease. Lancet Neurol. 2021;20(5):385\u201397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2.","journal-title":"Lancet Neurol"},{"issue":"2","key":"866_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/mds.29683","volume":"39","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Goetz CG, Mestre TA, et al. A statement of the MDS on biological definition, staging, and classification of parkinson\u2019s disease. Mov Disord. 2024;39(2):259\u201366. https:\/\/doi.org\/10.1002\/mds.29683.","journal-title":"Mov Disord"},{"issue":"2","key":"866_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer P. The \u03b1-Synuclein origin and connectome model (SOC model) of parkinson\u2019s disease: explaining motor asymmetry, Non-Motor phenotypes, and cognitive decline. J Parkinson\u2019s Disease. 2021;11(2):455\u201374. https:\/\/doi.org\/10.3233\/JPD-202481.","journal-title":"J Parkinson\u2019s Disease"},{"issue":"3","key":"866_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","volume":"23","author":"C Challis","year":"2020","unstructured":"Challis C, Hori A, Sampson TR, et al. Gut-seeded \u03b1-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci. 2020;23(3):327\u201336. https:\/\/doi.org\/10.1038\/s41593-020-0589-7.","journal-title":"Nat Neurosci"},{"issue":"6","key":"866_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","volume":"128","author":"S Holmqvist","year":"2014","unstructured":"Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the Gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128(6):805\u201320. https:\/\/doi.org\/10.1007\/s00401-014-1343-6.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"866_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim S, Kwon SH, Kam TI, et al. Transneuronal propagation of pathologic \u03b1-Synuclein from the gut to the brain models parkinson\u2019s disease. Neuron. 2019;103(4):627\u2013e6417. https:\/\/doi.org\/10.1016\/j.neuron.2019.05.035.","journal-title":"Neuron"},{"key":"866_CR10","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.nbd.2021.105599","volume":"163","author":"N Van Den Berge","year":"2022","unstructured":"Van Den Berge N, Ulusoy A. Animal models of brain-first and body-first parkinson\u2019s disease. Neurobiol Dis. 2022;163:105599. https:\/\/doi.org\/10.1016\/j.nbd.2021.105599.","journal-title":"Neurobiol Dis"},{"key":"866_CR11","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.nbd.2021.105557","volume":"161","author":"P Borghammer","year":"2021","unstructured":"Borghammer P, Horsager J, Andersen K, et al. Neuropathological evidence of body-first vs. brain-first lewy body disease. Neurobiol Dis. 2021;161:105557. https:\/\/doi.org\/10.1016\/j.nbd.2021.105557.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"866_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"Parkinson Progression Marker Initiative","year":"2011","unstructured":"Parkinson Progression Marker Initiative. The Parkinson progression marker initiative (PPMI). Prog Neurobiol. 2011;95(4):629\u201335. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.09.005.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"866_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes - key to Understanding heterogeneity. Nat Rev Neurol. 2021;17(6):349\u201361. https:\/\/doi.org\/10.1038\/s41582-021-00486-9.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"866_CR14","doi-asserted-by":"publisher","first-page":"e0246881","DOI":"10.1371\/journal.pone.0246881","volume":"16","author":"JW Lee","year":"2021","unstructured":"Lee JW, Song YS, Kim H, Ku BD, Lee WW. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early parkinson\u2019s disease: analysis of the PPMI data. PLoS ONE. 2021;16(2):e0246881. https:\/\/doi.org\/10.1371\/journal.pone.0246881.","journal-title":"PLoS ONE"},{"issue":"3","key":"866_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/genes13030471","volume":"13","author":"F Jia","year":"2022","unstructured":"Jia F, Fellner A, Kumar KR. Monogenic parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes (Basel). 2022;13(3):471. https:\/\/doi.org\/10.3390\/genes13030471.","journal-title":"Genes (Basel)"},{"issue":"15","key":"866_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"issue":"8","key":"866_CR17","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1002\/hbm.22822","volume":"36","author":"JB Pereira","year":"2015","unstructured":"Pereira JB, Aarsland D, Ginestet CE, et al. Aberrant cerebral network topology and mild cognitive impairment in early parkinson\u2019s disease. Hum Brain Mapp. 2015;36(8):2980\u201395. https:\/\/doi.org\/10.1002\/hbm.22822.","journal-title":"Hum Brain Mapp"},{"issue":"6","key":"866_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10072-017-2886-9","volume":"38","author":"K Li","year":"2017","unstructured":"Li K, Li SH, Su W, Chen HB. Diagnostic accuracy of REM sleep behaviour disorder screening questionnaire: a meta-analysis. Neurol Sci. 2017;38(6):1039\u201346. https:\/\/doi.org\/10.1007\/s10072-017-2886-9.","journal-title":"Neurol Sci"},{"issue":"11","key":"866_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.20153","volume":"19","author":"M Visser","year":"2004","unstructured":"Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in parkinson\u2019s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306\u201312. https:\/\/doi.org\/10.1002\/mds.20153.","journal-title":"Mov Disord"},{"issue":"3","key":"866_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1212\/WNL.0b013e3181ae7af1","volume":"73","author":"AH Rajput","year":"2009","unstructured":"Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology. 2009;73(3):206\u201312. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ae7af1.","journal-title":"Neurology"},{"issue":"12","key":"866_CR21","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00415-014-7513-6","volume":"261","author":"T Herman","year":"2014","unstructured":"Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM. Gait and balance in parkinson\u2019s disease subtypes: objective measures and classification considerations. J Neurol. 2014;261(12):2401\u201310. https:\/\/doi.org\/10.1007\/s00415-014-7513-6.","journal-title":"J Neurol"},{"issue":"3","key":"866_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mds.27617","volume":"34","author":"J Hoogland","year":"2019","unstructured":"Hoogland J, Boel JA, de Bie RMA, et al. Risk of parkinson\u2019s disease dementia related to level I MDS PD-MCI. Mov Disord. 2019;34(3):430\u20135. https:\/\/doi.org\/10.1002\/mds.27617.","journal-title":"Mov Disord"},{"issue":"3","key":"866_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, et al. Diagnostic criteria for mild cognitive impairment in parkinson\u2019s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349\u201356. https:\/\/doi.org\/10.1002\/mds.24893.","journal-title":"Mov Disord"},{"issue":"3","key":"866_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/157015908785777193","volume":"6","author":"ER Samuels","year":"2008","unstructured":"Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and Pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6(3):254\u201385. https:\/\/doi.org\/10.2174\/157015908785777193.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"866_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3233\/JPD-212761","volume":"11","author":"K Knudsen","year":"2021","unstructured":"Knudsen K, Fedorova TD, Horsager J, et al. Asymmetric dopaminergic dysfunction in Brain-First versus Body-First parkinson\u2019s disease subtypes. J Parkinsons Dis. 2021;11(4):1677\u201387. https:\/\/doi.org\/10.3233\/JPD-212761.","journal-title":"J Parkinsons Dis"},{"issue":"21","key":"866_CR26","doi-asserted-by":"publisher","first-page":"12928","DOI":"10.3390\/ijms232112928","volume":"23","author":"A Scott-Massey","year":"2022","unstructured":"Scott-Massey A, Boag MK, Magnier A, Bispo DPCF, Khoo TK, Pountney DL. Glymphatic system dysfunction and sleep disturbance May contribute to the pathogenesis and progression of parkinson\u2019s disease. Int J Mol Sci. 2022;23(21):12928. https:\/\/doi.org\/10.3390\/ijms232112928.","journal-title":"Int J Mol Sci"},{"issue":"6465","key":"866_CR27","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.aax5440","volume":"366","author":"NE Fultz","year":"2019","unstructured":"Fultz NE, Bonmassar G, Setsompop K, et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science. 2019;366(6465):628\u201331. https:\/\/doi.org\/10.1126\/science.aax5440.","journal-title":"Science"},{"key":"866_CR28","doi-asserted-by":"publisher","first-page":"RP87188","DOI":"10.7554\/eLife.87188","volume":"12","author":"D Ver\u00e9b","year":"2023","unstructured":"Ver\u00e9b D, Mijalkov M, Canal-Garcia A, et al. Age-related differences in the functional topography of the locus coeruleus and their implications for cognitive and affective functions. Elife. 2023;12:RP87188. https:\/\/doi.org\/10.7554\/eLife.87188.","journal-title":"Elife"},{"issue":"Suppl 1","key":"866_CR29","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.neuroimage.2004.07.051","volume":"23","author":"SM Smith","year":"2004","unstructured":"Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004;23(Suppl 1):S208\u2013219. https:\/\/doi.org\/10.1016\/j.neuroimage.2004.07.051.","journal-title":"NeuroImage"},{"issue":"2","key":"866_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s1361-8415(01)00036-6","volume":"5","author":"M Jenkinson","year":"2001","unstructured":"Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5(2):143\u201356. https:\/\/doi.org\/10.1016\/s1361-8415(01)00036-6.","journal-title":"Med Image Anal"},{"issue":"3","key":"866_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hbm.10062","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143\u201355. https:\/\/doi.org\/10.1002\/hbm.10062.","journal-title":"Hum Brain Mapp"},{"key":"866_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.neuroimage.2015.02.063","volume":"112","author":"RHR Pruim","year":"2015","unstructured":"Pruim RHR, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative strategies for motion artifact removal in resting state fMRI. NeuroImage. 2015;112:278\u201387. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.02.063.","journal-title":"NeuroImage"},{"key":"866_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.neuroimage.2015.02.064","volume":"112","author":"RHR Pruim","year":"2015","unstructured":"Pruim RHR, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI data. NeuroImage. 2015;112:267\u201377. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.02.064.","journal-title":"NeuroImage"},{"key":"866_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neurobiolaging.2021.11.006","volume":"112","author":"MJ Dahl","year":"2022","unstructured":"Dahl MJ, Mather M, Werkle-Bergner M, et al. Locus coeruleus integrity is related to Tau burden and memory loss in autosomal-dominant alzheimer\u2019s disease. Neurobiol Aging. 2022;112:39\u201354. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.11.006.","journal-title":"Neurobiol Aging"},{"key":"866_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neuroimage.2017.06.075","volume":"170","author":"KV Haak","year":"2018","unstructured":"Haak KV, Marquand AF, Beckmann CF. Connectopic mapping with resting-state fMRI. NeuroImage. 2018;170:83\u201394. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.06.075.","journal-title":"NeuroImage"},{"issue":"7615","key":"866_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nature18933","volume":"536","author":"MF Glasser","year":"2016","unstructured":"Glasser MF, Coalson TS, Robinson EC, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536(7615):171\u20138. https:\/\/doi.org\/10.1038\/nature18933.","journal-title":"Nature"},{"issue":"6","key":"866_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1162\/089976603321780317","volume":"15","author":"M Belkin","year":"2003","unstructured":"Belkin M, Niyogi P. Laplacian eigenmaps for dimensionality reduction and data representation. Neural Comput. 2003;15(6):1373\u201396. https:\/\/doi.org\/10.1162\/089976603321780317.","journal-title":"Neural Comput"},{"key":"866_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neuroimage.2017.08.009","volume":"161","author":"I Huertas","year":"2017","unstructured":"Huertas I, Oldehinkel M, van Oort ESB, et al. A bayesian Spatial model for neuroimaging data based on biologically informed basis functions. NeuroImage. 2017;161:134\u201348. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.08.009.","journal-title":"NeuroImage"},{"key":"866_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cortex.2019.04.015","volume":"119","author":"I Prze\u017adzik","year":"2019","unstructured":"Prze\u017adzik I, Faber M, Fern\u00e1ndez G, Beckmann CF, Haak KV. The functional organisation of the hippocampus along its long axis is gradual and predicts recollection. Cortex. 2019;119:324\u201335. https:\/\/doi.org\/10.1016\/j.cortex.2019.04.015.","journal-title":"Cortex"},{"issue":"8","key":"866_CR40","doi-asserted-by":"publisher","first-page":"0146","DOI":"10.1038\/s41562-017-0146","volume":"1","author":"AF Marquand","year":"2017","unstructured":"Marquand AF, Haak KV, Beckmann CF. Functional corticostriatal connection topographies predict goal directed behaviour in humans. Nat Hum Behav. 2017;1(8):0146. https:\/\/doi.org\/10.1038\/s41562-017-0146.","journal-title":"Nat Hum Behav"},{"key":"866_CR41","doi-asserted-by":"publisher","first-page":"e71846","DOI":"10.7554\/eLife.71846","volume":"11","author":"M Oldehinkel","year":"2022","unstructured":"Oldehinkel M, Llera A, Faber M, et al. Mapping dopaminergic projections in the human brain with resting-state fMRI. Elife. 2022;11:e71846. https:\/\/doi.org\/10.7554\/eLife.71846.","journal-title":"Elife"},{"issue":"12","key":"866_CR42","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acn3.644","volume":"5","author":"K Marek","year":"2018","unstructured":"Marek K, Chowdhury S, Siderowf A, et al. The parkinson\u2019s progression markers initiative (PPMI)\u2013 establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5(12):1460\u201377. https:\/\/doi.org\/10.1002\/acn3.644.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6512","key":"866_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abb8739","volume":"370","author":"M Nedergaard","year":"2020","unstructured":"Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50\u20136. https:\/\/doi.org\/10.1126\/science.abb8739.","journal-title":"Science"},{"issue":"4","key":"866_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11604-017-0617-z","volume":"35","author":"T Taoka","year":"2017","unstructured":"Taoka T, Masutani Y, Kawai H, et al. Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in alzheimer\u2019s disease cases. Jpn J Radiol. 2017;35(4):172\u20138. https:\/\/doi.org\/10.1007\/s11604-017-0617-z.","journal-title":"Jpn J Radiol"},{"key":"866_CR45","doi-asserted-by":"publisher","unstructured":"Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for parkinson\u2019s disease. Nat Genet. 2014;46(9):989\u201393https:\/\/doi.org\/10.1038\/ng.3043.","DOI":"10.1038\/ng.3043."},{"issue":"12","key":"866_CR46","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(19)30320-5.","journal-title":"Lancet Neurol"},{"key":"866_CR47","doi-asserted-by":"publisher","unstructured":"Chang YW, Zufiria-Gerbol\u00e8s B, G\u00d3mez-Ruiz E, et al. BRAPH 2: a flexible, open-source, reproducible, community-oriented, easy-to-use framework for network analyses, in neuroscience.https:\/\/doi.org\/10.1101\/2025.04.11.64845.","DOI":"10.1101\/2025.04.11.64845"},{"key":"866_CR48","doi-asserted-by":"publisher","unstructured":"Kingma DP, Welling M. Auto-Encoding variational Bayes. Published Online Dec. 2022;10. https:\/\/doi.org\/10.48550\/arXiv.1312.6114.","DOI":"10.48550\/arXiv.1312.6114"},{"key":"866_CR49","unstructured":"Midtvedt B, Pineda J, Klein Moberg H et al. Deep Learning Crash Course. No Starch Press. 2025. Accessed September 22, 2024. https:\/\/nostarch.com\/deep-learning-crash-course"},{"issue":"1","key":"866_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"issue":"4","key":"866_CR51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.5664\/jcsm.10424","volume":"19","author":"M Howell","year":"2023","unstructured":"Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2023;19(4):759\u201368. https:\/\/doi.org\/10.5664\/jcsm.10424.","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"866_CR52","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","volume":"132","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of parkinson\u2019s disease: 5 year follow-up of the campaign cohort. Brain. 2009;132(11):2958\u201369. https:\/\/doi.org\/10.1093\/brain\/awp245.","journal-title":"Brain"},{"issue":"2","key":"866_CR53","doi-asserted-by":"publisher","first-page":"eaav5447","DOI":"10.1126\/sciadv.aav5447","volume":"5","author":"LM Hablitz","year":"2019","unstructured":"Hablitz LM, Vinitsky HS, Sun Q, et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci Adv. 2019;5(2):eaav5447. https:\/\/doi.org\/10.1126\/sciadv.aav5447.","journal-title":"Sci Adv"},{"issue":"5","key":"866_CR54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/jnnp-2013-306104","volume":"85","author":"M Rolinski","year":"2014","unstructured":"Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560\u20136. https:\/\/doi.org\/10.1136\/jnnp-2013-306104.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"866_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2021.05.016","volume":"88","author":"R von Coelln","year":"2021","unstructured":"von Coelln R, Gruber-Baldini AL, Reich SG, Armstrong MJ, Savitt JM, Shulman LM. The inconsistency and instability of parkinson\u2019s disease motor subtypes. Parkinsonism Relat Disord. 2021;88:13\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.05.016.","journal-title":"Parkinsonism Relat Disord"},{"key":"866_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","volume":"28","author":"T Simuni","year":"2016","unstructured":"Simuni T, Caspell-Garcia C, Coffey C, et al. How stable are parkinson\u2019s disease subtypes in de Novo patients: analysis of the PPMI cohort? Parkinsonism Relat Disord. 2016;28:62\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.027.","journal-title":"Parkinsonism Relat Disord"},{"issue":"21","key":"866_CR57","doi-asserted-by":"publisher","first-page":"R1051","DOI":"10.1016\/j.cub.2015.09.039","volume":"25","author":"LA Schwarz","year":"2015","unstructured":"Schwarz LA, Luo L. Organization of the locus Coeruleus-Norepinephrine system. Curr Biol. 2015;25(21):R1051\u20136. https:\/\/doi.org\/10.1016\/j.cub.2015.09.039.","journal-title":"Curr Biol"},{"issue":"42","key":"866_CR58","doi-asserted-by":"publisher","first-page":"8239","DOI":"10.1523\/JNEUROSCI.1164-19.2019","volume":"39","author":"DJ Chandler","year":"2019","unstructured":"Chandler DJ, Jensen P, McCall JG, Pickering AE, Schwarz LA, Totah NK. Redefining noradrenergic neuromodulation of behavior: impacts of a modular locus coeruleus architecture. J Neurosci. 2019;39(42):8239\u201349. https:\/\/doi.org\/10.1523\/JNEUROSCI.1164-19.2019.","journal-title":"J Neurosci"},{"issue":"4","key":"866_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaneurol.2013.6233","volume":"71","author":"MA Thenganatt","year":"2014","unstructured":"Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499\u2013504. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6233.","journal-title":"JAMA Neurol"},{"issue":"3","key":"866_CR60","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.29708","volume":"39","author":"C Marras","year":"2024","unstructured":"Marras C, Fereshtehnejad SM, Berg D, et al. Transitioning from subtyping to precision medicine in parkinson\u2019s disease: A Purpose-Driven approach. Mov Disord. 2024;39(3):462\u201371. https:\/\/doi.org\/10.1002\/mds.29708.","journal-title":"Mov Disord"},{"key":"866_CR61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.parkreldis.2018.07.009","volume":"56","author":"TA Mestre","year":"2018","unstructured":"Mestre TA, Eberly S, Tanner C, et al. Reproducibility of data-driven parkinson\u2019s disease subtypes for clinical research. Parkinsonism Relat Disord. 2018;56:102\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.009.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"866_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JPD-202472","volume":"11","author":"TA Mestre","year":"2021","unstructured":"Mestre TA, Fereshtehnejad SM, Berg D, et al. Parkinson\u2019s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis. 2021;11(2):395\u2013404. https:\/\/doi.org\/10.3233\/JPD-202472.","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"866_CR63","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143(10):3077\u201388. https:\/\/doi.org\/10.1093\/brain\/awaa238.","journal-title":"Brain"},{"key":"866_CR64","doi-asserted-by":"publisher","first-page":"105626","DOI":"10.1016\/j.nbd.2022.105626","volume":"164","author":"J Horsager","year":"2022","unstructured":"Horsager J, Knudsen K, Sommerauer M. Clinical and imaging evidence of brain-first and body-first parkinson\u2019s disease. Neurobiol Dis. 2022;164:105626. https:\/\/doi.org\/10.1016\/j.nbd.2022.105626.","journal-title":"Neurobiol Dis"},{"key":"866_CR65","doi-asserted-by":"publisher","unstructured":"Banwinkler M, Dzialas V, Parkinson\u2019s Progression Markers Initiative, Hoenig MC, van Eimeren T. Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson\u2019s Disease Subtypes. Mov Disord. Published online August 9, 2022. https:\/\/doi.org\/10.1002\/mds.29172","DOI":"10.1002\/mds.29172"},{"issue":"1","key":"866_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/mds.26374","volume":"31","author":"MA Nalls","year":"2016","unstructured":"Nalls MA, Keller MF, Hernandez DG, et al. Baseline genetic associations in the parkinson\u2019s progression markers initiative (PPMI). Mov Disord. 2016;31(1):79\u201385. https:\/\/doi.org\/10.1002\/mds.26374.","journal-title":"Mov Disord"},{"issue":"8","key":"866_CR67","doi-asserted-by":"publisher","first-page":"evae147","DOI":"10.1093\/gbe\/evae147","volume":"16","author":"C Di","year":"2024","unstructured":"Di C, Lohmueller KE. Revisiting dominance in population genetics. Genome Biol Evol. 2024;16(8):evae147. https:\/\/doi.org\/10.1093\/gbe\/evae147.","journal-title":"Genome Biol Evol"},{"issue":"1","key":"866_CR68","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41467-023-36424-0","volume":"14","author":"S Kang","year":"2023","unstructured":"Kang S, Kim J, Park A, et al. TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity. Nat Commun. 2023;14(1):700. https:\/\/doi.org\/10.1038\/s41467-023-36424-0.","journal-title":"Nat Commun"},{"key":"866_CR69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.molimm.2021.10.012","volume":"140","author":"J Shen","year":"2021","unstructured":"Shen J, Wu Q, Liang T, et al. TRIM40 inhibits IgA1-induced proliferation of glomerular mesangial cells by inactivating NLRP3 inflammasome through ubiquitination. Mol Immunol. 2021;140:225\u201332. https:\/\/doi.org\/10.1016\/j.molimm.2021.10.012.","journal-title":"Mol Immunol"},{"issue":"1","key":"866_CR70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mds.29620","volume":"39","author":"Y Yang","year":"2024","unstructured":"Yang Y, Stewart T, Zhang C, et al. Erythrocytic \u03b1-Synuclein and the gut microbiome: kindling of the gut-Brain Axis in parkinson\u2019s disease. Mov Disord. 2024;39(1):40\u201352. https:\/\/doi.org\/10.1002\/mds.29620.","journal-title":"Mov Disord"},{"issue":"14","key":"866_CR71","doi-asserted-by":"publisher","first-page":"e2121946119","DOI":"10.1073\/pnas.2121946119","volume":"119","author":"L Nagpal","year":"2022","unstructured":"Nagpal L, Kornberg MD, Snyder SH. Inositol hexakisphosphate kinase-2 non-catalytically regulates mitophagy by attenuating PINK1 signaling. Proc Natl Acad Sci U S A. 2022;119(14):e2121946119. https:\/\/doi.org\/10.1073\/pnas.2121946119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"866_CR72","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey RP, Lee JC. Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. Proc Natl Acad Sci U S A. 2015;112(30):9322\u20137. https:\/\/doi.org\/10.1073\/pnas.1500937112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"866_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/brain\/awz350","volume":"143","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Reed X, Krohn L, et al. Genetic modifiers of risk and age at onset in GBA associated parkinson\u2019s disease and lewy body dementia. Brain. 2020;143(1):234\u201348. https:\/\/doi.org\/10.1093\/brain\/awz350.","journal-title":"Brain"},{"key":"866_CR74","doi-asserted-by":"publisher","unstructured":"Jones-Tabah J, He K, Senkevich K et al. The Parkinson\u2019s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. bioRxiv. Published online November 15, 2023:2023.11.11.566693. https:\/\/doi.org\/10.1101\/2023.11.11.566693","DOI":"10.1101\/2023.11.11.566693"},{"issue":"1","key":"866_CR75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-024-00648-8","volume":"10","author":"PJ Kearney","year":"2024","unstructured":"Kearney PJ, Zhang Y, Liang M, et al. Silencing parkinson\u2019s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability. NPJ Parkinsons Dis. 2024;10(1):41. https:\/\/doi.org\/10.1038\/s41531-024-00648-8.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"866_CR76","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41531-023-00484-2","volume":"9","author":"J Obergasteiger","year":"2023","unstructured":"Obergasteiger J, Castonguay AM, Pizzi S, et al. The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. NPJ Parkinsons Dis. 2023;9(1):44. https:\/\/doi.org\/10.1038\/s41531-023-00484-2.","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"866_CR77","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.25037","volume":"27","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913\u20136. https:\/\/doi.org\/10.1002\/mds.25037.","journal-title":"Mov Disord"},{"issue":"16","key":"866_CR78","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/mds.21740","volume":"22","author":"K Stiasny-Kolster","year":"2007","unstructured":"Stiasny-Kolster K, Mayer G, Sch\u00e4fer S, M\u00f6ller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire\u2013a new diagnostic instrument. Mov Disord. 2007;22(16):2386\u201393. https:\/\/doi.org\/10.1002\/mds.21740.","journal-title":"Mov Disord"},{"issue":"2","key":"866_CR79","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1468-1331.2009.02788.x","volume":"17","author":"C Rodriguez-Blazquez","year":"2010","unstructured":"Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-Cuesta J, Martinez-Martin P. Longitudinal parkinson\u2019s disease patient study, estudio longitudinal de pacients Con enfermedad Da Parkinson group. Independent validation of the scales for outcomes in parkinson\u2019s disease-autonomic (SCOPA-AUT). Eur J Neurol. 2010;17(2):194\u2013201. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02788.x.","journal-title":"Eur J Neurol"},{"key":"866_CR80","doi-asserted-by":"publisher","first-page":"106655","DOI":"10.1016\/j.nbd.2024.106655","volume":"201","author":"DG Park","year":"2024","unstructured":"Park DG, Kang W, Shin IJ, et al. Difference in gut microbial dysbiotic patterns between body-first and brain-first parkinson\u2019s disease. Neurobiol Dis. 2024;201:106655. https:\/\/doi.org\/10.1016\/j.nbd.2024.106655.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"866_CR81","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ana.27006","volume":"96","author":"E Camerucci","year":"2024","unstructured":"Camerucci E, Mullan AF, Turcano P, et al. A Population-Based approach to the argument on Brain-First and body-First pathogenesis of lewy body disease. Ann Neurol. 2024;96(3):551\u20139. https:\/\/doi.org\/10.1002\/ana.27006.","journal-title":"Ann Neurol"},{"issue":"1","key":"866_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00730-1","volume":"10","author":"Z Xu","year":"2024","unstructured":"Xu Z, Hu T, Xu C, et al. Disease progression in proposed brain-first and body-first parkinson\u2019s disease subtypes. Npj Parkinsons Dis. 2024;10(1):1\u20135. https:\/\/doi.org\/10.1038\/s41531-024-00730-1.","journal-title":"Npj Parkinsons Dis"}],"updated-by":[{"DOI":"10.1186\/s13024-025-00885-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000}}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00866-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00866-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00866-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:53:42Z","timestamp":1781610822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-025-00866-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00866-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13024-025-00885-2","URL":"https:\/\/doi.org\/10.1186\/s13024-025-00885-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study analysed data from the Parkinson Progression Marker Initiative (PPMI), a publicly available dataset. The PPMI study was approved by the institutional review boards of all participating sites, and informed consent was obtained from all participants prior to inclusion in the study. The study complies with ethical standards for research involving human participants, and the original study\u2019s ethics committee approval and informed consent documentation apply to this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain data from any individual person in any form (including details, images, or videos).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}